TAC-T Cells for Solid Tumors

Time: 3:30 pm
day: Day One


  • Key advantages of T cells engineered with the TAC (T Cell Antigen Coupler) receptor to treat solid tumors
  • Development status of TAC01-HER2, a HER2-directed TAC-T cell product in a Phase I clinical trial
  • Identification and development of novel TAC receptors against safe solid tumor antigens